Strategic Blueprint’s Aquestive Therapeutics AQST Stock Holding History

Strategic Blueprint’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9	Closed	–	–	457
2021 Q2	$0	Buy	+9	New	+$36	﹤0.01%	1410

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCL

Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Latash Investments Anchorage, Alaska $129M AUM 14.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Strategic Blueprint's AQST Position: Q3 2021 in Review

Strategic Blueprint sold out of Aquestive Therapeutics (AQST) in Q3 2021, closing a stake of 9 shares.

Strategic Blueprint first reported a position in AQST in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 46 funds tracked by Wall St. Rank hold AQST as of Q3 2021.

Strategic Blueprint reported no remaining Aquestive Therapeutics position as of Q3 2021 after selling out during the quarter.
Strategic Blueprint sold 9 Aquestive Therapeutics shares in Q3 2021.
Strategic Blueprint first reported a position in Aquestive Therapeutics in Q2 2021 and held it in 1 quarter.
Strategic Blueprint's Aquestive Therapeutics position peaked at $0 in Q2 2021.
46 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2021.

Based on Strategic Blueprint's 13F filing for Q3 2021, filed 12 Nov 2021.